News

Victoria L Tseng, MD, PhD, assistant professor of ophthalmology and a glaucoma specialist at UCLA and scientist at Doheny Eye Institute, spoke with the Eye Care Network at this year's AAO meeting about the "Glaucoma Original Papers" session and discussed the papers presented in the session by Giovanni Montesano, MD; Jason D Horowitz, MD; Christopher M Edwards, BS; Eamonn Thomas Fahy, BMBCH; Kiana Tavakoli, MD; Hani El Helwe, MD; and Joseph F Panarelli, MD.

John Josephson, MD, from the Eye Specialists and Surgeons of Northern Virginia, shared insights on office-based surgeries and how it allows for the addition of new technologies and new procedures at this year's AAO meeting held in Chicago, Illinois.

Brian Francis, MD, from the Doheny Eye Institute and the UCLA Department of Ophthalmology, shared insights on MIGS techniques and the labs and didactic available while at this year's AAO meeting held in Chicago, Illinois.

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein occlusions, in young adults who consume numerous energy drinks.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Henderson’s presentation touches on the shift in medical education from traditional learning to AI and robotics.

Weijie Violet Lin, MD, presented findings from her research, which revealed that post-cross-linking complications were low and highlighted key risk factors and the importance of early identification to enhance long-term patient outcomes.

CBNS, such as turmeric, are natural anti-inflammatory and antioxidant agents that may confer benefits against AMD.

At the American Academy of Ophthalmology (AAO) meeting in Chicago, Illinois, Brent Kramer, MD, he talked with the Eye Care Network about using the MKO Melt in lieu of IV anaesthesia ahead of ocular surgery.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

A time line marked by innovation, collaboration, and improving patient outcomes.

Victoria L. Tseng, MD, PhD, discusses SLT, microshunts and what glaucoma specialists can learn from large data sets

According to the company, the second Phase 3 LUCIA pivotal trial first patient dosing is expected by end of 2024 with topline data anticipated in 2026.

During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr., MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.

A study clarifies the relationship between postnatal weight gain and ROP development.

Constance O. Okeke, MD, shared insights from on her presentation entitled, "Reduction in IOP after switching to latanoprostene bunod in glaucoma patients in real-world clinical practice," which was given at the American Academy of Ophthalmology held in Chicago, Illinois.

Brent Kramer, MD, presents on an alternative to IV sedation for cataract surgeries and complex cases

The study, conducted in 2022, highlights significant variations in glaucoma prevalence across different demographic groups, states, and counties.

In a paper presented at the American Academy of Ophthalmology annual meeting in Chicago, Jonathan Tan, a third year medical student at the Icahn School of Medicine at Mount Sinai detailed the study on ophthalmic eye drop waste in clinics, revealing 72% medication loss due to outdated 28-day expiration guidelines, resulting in significant financial waste. The study advocates following FDA expiration dates.

Michael Singer, MD, shared insights from his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

This year’s conference in Chicago showcased a diverse array of practice-changing data across multiple ophthalmic specialties, including advances in cataract surgery, glaucoma management, and retinal disease treatments.

In a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).